186 related articles for article (PubMed ID: 28577946)
1. Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer.
Ziemke M; Patil T; Nolan K; Tippimanchai D; Malkoski SP
Lung Cancer; 2017 Jul; 109():28-35. PubMed ID: 28577946
[TBL] [Abstract][Full Text] [Related]
2. Smad4 loss promotes lung cancer formation but increases sensitivity to DNA topoisomerase inhibitors.
Haeger SM; Thompson JJ; Kalra S; Cleaver TG; Merrick D; Wang XJ; Malkoski SP
Oncogene; 2016 Feb; 35(5):577-586. PubMed ID: 25893305
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol Enhances Etoposide-Induced Cytotoxicity through Down-Regulating ERK1/2 and AKT-Mediated X-ray Repair Cross-Complement Group 1 (XRCC1) Protein Expression in Human Non-Small-Cell Lung Cancer Cells.
Ko JC; Syu JJ; Chen JC; Wang TJ; Chang PY; Chen CY; Jian YT; Jian YJ; Lin YW
Basic Clin Pharmacol Toxicol; 2015 Dec; 117(6):383-91. PubMed ID: 26046675
[TBL] [Abstract][Full Text] [Related]
4. Association of GSTP1 and RRM1 Polymorphisms with the Response and Toxicity of Gemcitabine-cisplatin Combination Chemotherapy in Chinese Patients with Non-small Cell Lung Cancer.
Yuan ZJ; Zhou WW; Liu W; Wu BP; Zhao J; Wu W; He Y; Yang S; Su J; Luo Y
Asian Pac J Cancer Prev; 2015; 16(10):4347-51. PubMed ID: 26028097
[TBL] [Abstract][Full Text] [Related]
5. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.
Joerger M; deJong D; Burylo A; Burgers JA; Baas P; Huitema AD; Beijnen JH; Schellens JH
Lung Cancer; 2011 Nov; 74(2):310-7. PubMed ID: 21529986
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy in combination with gemcitabine in non-small cell lung cancer.
Rosell R; Crino L; Danenberg K; Scagliotti G; Bepler G; Taron M; Alberola V; Provencio M; Camps C; De Marinis F; Sanchez JJ; Peñas R
Semin Oncol; 2003 Aug; 30(4 Suppl 10):19-25. PubMed ID: 12917817
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy resistance and oncogene expression in non-small cell lung cancer.
d'Amato TA; Landreneau RJ; Ricketts W; Huang W; Parker R; Mechetner E; Yu IR; Luketich JD
J Thorac Cardiovasc Surg; 2007 Feb; 133(2):352-63. PubMed ID: 17258563
[TBL] [Abstract][Full Text] [Related]
8. SMAD4 mutation correlates with poor prognosis in non-small cell lung cancer.
Wang Y; Xue Q; Zheng Q; Jin Y; Shen X; Yang M; Zhou X; Li Y
Lab Invest; 2021 Apr; 101(4):463-476. PubMed ID: 33303972
[TBL] [Abstract][Full Text] [Related]
9. Preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for the treatment of NSCLC.
Samakoglu S; Deevi DS; Li H; Wang S; Murphy M; Bao C; Bassi R; Prewett M; Tonra JR
Cancer Genomics Proteomics; 2012; 9(2):77-92. PubMed ID: 22399498
[TBL] [Abstract][Full Text] [Related]
10. Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy.
Ren S; Zhou S; Wu F; Zhang L; Li X; Zhang J; Xu J; Lv M; Zhang J; Zhou C
Lung Cancer; 2012 Jan; 75(1):102-9. PubMed ID: 21676483
[TBL] [Abstract][Full Text] [Related]
11. Topoisomerase inhibitor-induced apoptosis accompanied by down-regulation of Bcl-2 in human lung cancer cells.
Oizumi S; Isobe H; Ogura S; Ishida T; Yamazaki K; Nishimura M; Kawakami Y; Dosaka-Akita H
Anticancer Res; 2002; 22(6C):4029-37. PubMed ID: 12553028
[TBL] [Abstract][Full Text] [Related]
12. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
Zhang GB; Chen J; Wang LR; Li J; Li MW; Xu N; Wang Y; Shentu JZ
Cancer Chemother Pharmacol; 2012 May; 69(5):1277-87. PubMed ID: 22302408
[TBL] [Abstract][Full Text] [Related]
13. Genetic testing for chemotherapy in non-small cell lung cancer.
Rosell R; Taron M; Alberola V; Massuti B; Felip E
Lung Cancer; 2003 Aug; 41 Suppl 1():S97-102. PubMed ID: 12867068
[TBL] [Abstract][Full Text] [Related]
14. The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient.
Mlak R; Krawczyk P; Ciesielka M; Kozioł P; Homa I; Powrózek T; Prendecka M; Milanowski J; Małecka-Massalska T
Clin Transl Oncol; 2016 Sep; 18(9):915-24. PubMed ID: 26650486
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of circPVT1 in patients with non-small cell lung cancer who received cisplatin combined with gemcitabine chemotherapy.
Lu H; Xie X; Chen Q; Cai S; Liu S; Bao C; Luo J; Kong J
Tumori; 2021 Jun; 107(3):204-208. PubMed ID: 32734834
[TBL] [Abstract][Full Text] [Related]
16. Influence of genetic markers on survival in non-small cell lung cancer.
Rosell R; Taron M; Camps C; López-Vivanco G
Drugs Today (Barc); 2003 Oct; 39(10):775-86. PubMed ID: 14668933
[TBL] [Abstract][Full Text] [Related]
17. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer.
Stewart DJ; Tomiak E; Shamji FM; Maziak DE; MacLeod P
Lung Cancer; 2004 May; 44(2):241-9. PubMed ID: 15084389
[TBL] [Abstract][Full Text] [Related]
19. Effect evaluation of cisplatin-gemcitabine combination chemotherapy for advanced non-small cell lung cancer patients using microarray data.
Ma GF; Zhang RF; Ying KJ; Wang D
Eur Rev Med Pharmacol Sci; 2015 Feb; 19(4):578-85. PubMed ID: 25753874
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer.
Lee KH; Han SW; Hwang PG; Oh DY; Kim DW; Chung DH; Im SA; Kim TY; Heo DS; Bang YJ
Jpn J Clin Oncol; 2006 Jun; 36(6):344-50. PubMed ID: 16818479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
